Asim Roy, MD
Sleep Medicine · Dublin, OHNPI 1639159767
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 47.0% of the total. Reporting peaked in 2021 at $129,958 and has fallen 50.6% since, to $64,257 in 2025. Among sleep medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 792 payments — averaging $841.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$313K
- Inspire Medical Systems, Inc.$155K
- Harmony Biosciences LLC$80K
- Avadel CNS Pharmaceuticals, LLC$69K
- Eisai Inc.$16K
- Lilly USA, LLC$16K
- plus $17K from 18 others
Across 575 payments — averaging $2697.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$590K
- Takeda Pharmaceuticals U.S.A., Inc.$357K
- Harmony Biosciences LLC$142K
- Inspire Medical Systems, Inc.$128K
- Avadel CNS Pharmaceuticals, LLC$96K
- Noctrix Health, Inc.$80K
- plus $158K from 5 others
What the payments were for
- Consulting fees$266,45240%
- Speaking & faculty fees$336,53351%
- Travel & lodging$43,1526%
- Food & beverage$19,4613%
- Education$6520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 359 | $313,358 |
| Inspire Medical Systems, Inc. | 108 | $154,563 |
| Harmony Biosciences LLC | 137 | $80,274 |
| Avadel CNS Pharmaceuticals, LLC | 64 | $69,065 |
| Eisai Inc. | 29 | $16,222 |
| Lilly USA, LLC | 19 | $16,136 |
| Axsome Therapeutics, Inc. | 33 | $12,150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,254 |
| Resmed Corp | 1 | $1,000 |
| Vertex | 2 | $917 |
| Azurity Pharmaceuticals, Inc. | 12 | $240 |
| ZOLL Respicardia, Inc. | 6 | $212 |
| Respire Medical Holdings LLC | 1 | $193 |
| Noctrix Health, Inc. | 2 | $133 |
| Itamar Medical Inc | 1 | $118 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Arbor Pharmaceuticals, Inc. | 5 | $90 |
| Fisher & Paykel Healthcare Inc | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| 3b Medical, Inc. | 1 | $26 |
| Somnomed Inc. | 1 | $24 |
| Medicomp Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$666,250 in reported general payments places this provider in the 95th percentile of 94 sleep medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 60 | $873,805 |
| SunosiSolriamfetol Hcl | 32 | $33,436 |
| Modafinil | 44 | $18,315 |
| QuviviqDaridorexant Hcl | 22 | $10,631 |
| DayvigoLemborexant | 13 | $5,698 |
| Atomoxetine Hcl | 18 | $4,146 |
| Armodafinil | 28 | $1,932 |
| Pregabalin | 32 | $702 |
| Trazodone Hcl | 83 | $613 |
| Gabapentin | 51 | $565 |
| Doxepin Hcl | 26 | $534 |
| Zolpidem Tartrate ErZolpidem Tartrate | 21 | $460 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $445 |
| Methadone Hcl | 34 | $420 |
| Eszopiclone | 23 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $80,274 | $873,80560 claims |
| Axsome Therapeutics, Inc.Sunosi | $12,150 | $33,43632 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $31 | $10,63122 claims |
| Eisai Inc.Dayvigo | $16,222 | $5,69813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 sleep medicine providers in Ohio.
Other sleep medicine in Dublin
- Shikha MistryDublin$8K
- Shahrokh JavaheriCincinnati$404K
- Louis TartagliaMaumee$314K
- John AndrefskyParma$147K
- Anthony SuchoskiCincinnati$89K
- Nancy Foldvary-SchaeferCleveland$75K
- Shayla PullenCincinnati$71K
- Gautam SamadderColumbus$53K
- Kevin CarterBeavercreek$49K
- Brian ChenCleveland$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.